FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320857894> ?p ?o ?g. }

• W4320857894 endingPage "749" @default.
• W4320857894 startingPage "729" @default.
• W4320857894 abstract "Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a spectrum of burdensome dermatologic conditions. The US Food and Drug Administration (FDA) recently placed a black box warning on this class of medications due to safety concerns based on data from studies investigating tofacitinib in patients with rheumatoid arthritis. Here we provide an overview of the timeline of FDA approval of JAK inhibitors in dermatology. We also discuss the available safety profiles of approved oral JAK1 inhibitors, namely abrocitinib and upadacitinib, oral baricitinib, a JAK1/2 inhibitor, deucravacitinib, a Tyk2 inhibitor, and the topical JAK1/2 inhibitor ruxolitinib in dermatology patients. Additionally, we offer suggestions for initial screening and laboratory monitoring for patients receiving JAK inhibitors. We found that the rates of venous thromboembolism reported in trials ranged from no events to 0.1-0.5% in dermatology-specific phase 3 clinical trials compared with no events in the placebo. The rates of cardiovascular events ranged from no events to 0.4-1.2% compared with no events to 0.5-1.2% in the placebo. The rates of serious infections were 0.4-4.8% compared with no events to 0.5-1.3% in the placebo. The rates of nonmelanoma skin cancer (NMSC) ranged from no event to 0.6-0.9% compared with no events in the placebo. The rates of non-NMSC ranged from no event to 0.2-0.7% compared with no event to 0.6% in the placebo. Most patients who developed these adverse events had risk factors for the specific event. The most common adverse events of oral JAK inhibitors included upper respiratory infections, nasopharyngitis, nausea, headache, and acne. Dermatologists should consider patients' baseline risk factors for developing serious complications when prescribing oral JAK inhibitors." @default.
• W4320857894 created "2023-02-16" @default.
• W4320857894 creator A5069252128 @default.
• W4320857894 creator A5070925575 @default.
• W4320857894 creator A5082757307 @default.
• W4320857894 creator A5088597557 @default.
• W4320857894 date "2023-02-15" @default.
• W4320857894 modified "2023-10-10" @default.
• W4320857894 title "A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring" @default.
• W4320857894 cites W1534350202 @default.
• W4320857894 cites W1836238490 @default.
• W4320857894 cites W1892175722 @default.
• W4320857894 cites W1916572050 @default.
• W4320857894 cites W1948887633 @default.
• W4320857894 cites W1983163536 @default.
• W4320857894 cites W2017881569 @default.
• W4320857894 cites W2049804077 @default.
• W4320857894 cites W2117335168 @default.
• W4320857894 cites W2123946257 @default.
• W4320857894 cites W2124014177 @default.
• W4320857894 cites W2141682274 @default.
• W4320857894 cites W2158649716 @default.
• W4320857894 cites W2174132185 @default.
• W4320857894 cites W2215771248 @default.
• W4320857894 cites W2521655245 @default.
• W4320857894 cites W2524051065 @default.
• W4320857894 cites W2580870032 @default.
• W4320857894 cites W2610814011 @default.
• W4320857894 cites W2616574318 @default.
• W4320857894 cites W2892136519 @default.
• W4320857894 cites W2904559265 @default.
• W4320857894 cites W2991540591 @default.
• W4320857894 cites W2999917455 @default.
• W4320857894 cites W3017270234 @default.
• W4320857894 cites W3032018657 @default.
• W4320857894 cites W3036527747 @default.
• W4320857894 cites W3037349633 @default.
• W4320857894 cites W3044651017 @default.
• W4320857894 cites W3047229059 @default.
• W4320857894 cites W3081791594 @default.
• W4320857894 cites W3087665791 @default.
• W4320857894 cites W3094894293 @default.
• W4320857894 cites W3122981268 @default.
• W4320857894 cites W3137184272 @default.
• W4320857894 cites W3137301988 @default.
• W4320857894 cites W3154217309 @default.
• W4320857894 cites W3159897478 @default.
• W4320857894 cites W3161578803 @default.
• W4320857894 cites W3161796718 @default.
• W4320857894 cites W3162987242 @default.
• W4320857894 cites W3164101391 @default.
• W4320857894 cites W3164705475 @default.
• W4320857894 cites W3173504619 @default.
• W4320857894 cites W3194970552 @default.
• W4320857894 cites W3196275328 @default.
• W4320857894 cites W3196718449 @default.
• W4320857894 cites W3209484442 @default.
• W4320857894 cites W3216146155 @default.
• W4320857894 cites W4205276722 @default.
• W4320857894 cites W4206480106 @default.
• W4320857894 cites W4210529991 @default.
• W4320857894 cites W4220831188 @default.
• W4320857894 cites W4220948160 @default.
• W4320857894 cites W4224060947 @default.
• W4320857894 cites W4226034331 @default.
• W4320857894 cites W4282942340 @default.
• W4320857894 cites W4283658414 @default.
• W4320857894 cites W4284989117 @default.
• W4320857894 cites W4285110410 @default.
• W4320857894 cites W4290997453 @default.
• W4320857894 cites W4292940403 @default.
• W4320857894 cites W4295807681 @default.
• W4320857894 cites W4296686999 @default.
• W4320857894 cites W4296696831 @default.
• W4320857894 cites W4301150362 @default.
• W4320857894 cites W4306839892 @default.
• W4320857894 cites W4308639186 @default.
• W4320857894 doi "https://doi.org/10.1007/s13555-023-00892-5" @default.
• W4320857894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36790724" @default.
• W4320857894 hasPublicationYear "2023" @default.
• W4320857894 type Work @default.
• W4320857894 citedByCount "11" @default.
• W4320857894 countsByYear W43208578942023 @default.
• W4320857894 crossrefType "journal-article" @default.
• W4320857894 hasAuthorship W4320857894A5069252128 @default.
• W4320857894 hasAuthorship W4320857894A5070925575 @default.
• W4320857894 hasAuthorship W4320857894A5082757307 @default.
• W4320857894 hasAuthorship W4320857894A5088597557 @default.
• W4320857894 hasBestOaLocation W43208578941 @default.
• W4320857894 hasConcept C112392421 @default.
• W4320857894 hasConcept C126322002 @default.
• W4320857894 hasConcept C142724271 @default.
• W4320857894 hasConcept C16005928 @default.
• W4320857894 hasConcept C197934379 @default.
• W4320857894 hasConcept C204787440 @default.
• W4320857894 hasConcept C27081682 @default.
• W4320857894 hasConcept C2776112149 @default.
• W4320857894 hasConcept C2776233030 @default.

• next